title: Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients.
abstract: OBJECTIVE
  The aim of this study was to estimate the incidence of complications after (90)Y microsphere radioembolization for unresectable hepatic tumors and evaluate risk factors for late complications.
  
  
  METHODS
  A cohort of 112 consecutive patients from two institutions underwent (90)Y microsphere radioembolization for unresectable hepatic tumors. Complications were graded according to the Common Terminology Criteria for Adverse Events, version 3.0. Symptoms secondary to postradioembolization syndrome occurring within 30 days were recorded as early complications, and all other complications were considered late complications.
  
  
  RESULTS
  Seventy-eight patients (70%) experienced postradioembolization syndrome, including fatigue, abdominal pain, nausea, vomiting, anorexia, or fever. Three patients (3%) experienced a Grade 3 early complication; no Grade 4 or 5 early toxicity occurred. Two patients (2%) experienced clinically significant liver dysfunction; 13 patients (12%), 27 patients (24%), and 9 patients (8%) had an elevation of bilirubin, aspartate aminotransferase, and alanine aminotransferase, respectively. Eleven patients (10%) experienced gastrointestinal ulceration, including two Grade 3 complications and one Grade 4 complication. Cholecystitis occurred in 7 patients (6%), including two Grade 3 complications. Grade 2 pancreatitis occurred in 1 patient (1%). No radiation pneumonitis was observed. The cumulative incidence of late Grade 3 or 4 complications at 12 months after radioembolization was 8%. No Grade 5 toxicity occurred.
  
  
  CONCLUSIONS
  (90)Y microsphere radioembolization is a well-tolerated treatment for unresectable hepatic tumors with a low risk of Grade 3 or higher early or late toxicity.
authors: Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL. Electronic address: peterson.jennifer2@mayo.edu.
authors: Jennifer L
authors: JL
authors: Peterson
authors: Laura A
authors: LA
authors: Vallow
authors: Douglas W
authors: DW
authors: Johnson
authors: Michael G
authors: MG
authors: Heckman
authors: Nancy N
authors: NN
authors: Diehl
authors: Ashley A
authors: AA
authors: Smith
authors: Katherine S
authors: KS
authors: Tzou
authors: Ricardo
authors: R
authors: Paz-Fumagalli
authors: Siyong
authors: S
authors: Kim
authors: Stephen J
authors: SJ
authors: Ko
authors: Larry C
authors: LC
authors: Daugherty
authors: George P
authors: GP
authors: Kim
authors: Norman
authors: N
authors: Brown
authors: Kurt W
authors: KW
authors: Mori
authors: Steven J
authors: SJ
authors: Buskirk
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods*; D004621:Embolization, Therapeutic / Q000009:adverse effects* / Q000295:instrumentation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008113:Liver Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000209:etiology*; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D055815:Young Adult; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D015021:Yttrium Radioisotopes
keywords: (90)Y microsphere radioembolization; Liver metastases; Postradioembolization syndrome; Selective internal radiation therapy; Toxicity